All News

cancer search news magnify

Xeljanz Cancer Risks Detailed

MedPage Today

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Read Article
PSA068.jpg

Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis

Jack Cush, MD

Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.

Read Article
PSA2L.jpg

The Top 10 Research Priorities in Psoriatic Arthritis

Jack Cush, MD

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).

Read Article
cost.price_.biologic.injectable.jpg

Comparing Biosimilar Growth in the US, Germany, and Switzerland

Jack Cush, MD

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.

Read Article
pain

Pain in Psoriatic Arthritis

Patricia Harkins, MD

The prioritisation of pain, and its evaluation, is important in those with psoriatic arthritis, when the already incredibly heterogenous nature of the condition can complicate assessment. Whilst we lean towards all pain in PsA being nociceptive in nature, evidence suggests that a significant proportion of patients with PsA also have nociplastic pain, characterised by fibromyalgia.

Read Article
Sleep asleep

Sleep Quality & Psoriatic Arthritis

Olga Petryna, MD

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Read Article
Best of

ACR Best Abstracts - Day 3

Jack Cush, MD

The last day was jammed with important reports and research including the late breaking abstracts. 



 

Read Article
pills-384846_640%20%281%29.jpg

The complexity of opioid use in spondyloarthritis

Robert Chao, MD

A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the FORWARD databank. It sheds new light and leaves us with some food for thought

Read Article
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx

Links:

Dr. John Cush RheumNow ( View Tweet)
Sleep Quality & PsA Abstract #0387 presented at #ACR22 attempted to shed light in this important quality of life determinant. 247 adult PsA patients were included in this study and their sleep quality was measured using the PSQI questionnaire. https://t.co/lLTnrh2yxG https://t.co/9ViEnEFE6c

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow us on LinkedIn too! https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5

Links:

Dr. John Cush RheumNow ( View Tweet)
Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies https://t.co/3dwYmx7Hva https://t.co/ZFlFmWRbMK

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of #ACR22 Day 2 in PSA -Efficacy and Safety Results from BE OPTIMAL in PsA -JAK inhibitors in rheumatic diseases -Who is the Winner? Switch vs Cycle in PsA -Women vs. Men: Response to Treatment in Seronegative Arthritis and more. https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y

Links:

Dr. John Cush RheumNow ( View Tweet)
Topic Podcasts - PsA Part1 Best of PsA on Day 1 #ACR22 https://t.co/uXxUwy6u9G https://t.co/GDDXgcn2EC

Links:

Dr. John Cush RheumNow ( View Tweet)
Are MDA criteria created equal in PsA? Dr. Rachel Tate ( @uptoTate ) reviews abstract #1496: Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met? Presented at #ACR22. https://t.co/H4wPHEV8D5 https://t.co/NqXYxXRNEX

Links:

Dr. John Cush RheumNow ( View Tweet)
Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies https://t.co/Bw3RHp3lSR https://t.co/Yva84Iw8hk

Links:

Dr. John Cush RheumNow ( View Tweet)
Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor Dr. Sims ( @DrCassySims) discusses abstract 0199 presented at #ACR22. https://t.co/L14WoimRE6 https://t.co/LhgyE1LwGa

Links:

Dr. John Cush RheumNow ( View Tweet)
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa

Links:

Richard Conway RichardPAConway ( View Tweet)
Pain in #psoriaticarthritis might not be all inflammatory.. In this study presented by Dr F Sunzini: 👉PsA pts w/⬆️FM scores had⬆️functional brain connectivity bet mid-post IC & thalamus, phgyrus & PFC ..so consider nociplastic pain too & adjust mgt #ACR22 @RheumNow ABST#2256 https://t.co/suCAvx0pD5
sheila RHEUMarampa ( View Tweet)
BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA. Similar ACR 50 (~50%) response rates of Bimekizumab, adalimumab, and placebo (switched to BKZ at wk 16). ~60% PASI100 in BKZ #ACRBest Abs#L02 @RheumNow #ACR22 https://t.co/W2B2kyju9F
Robert B Chao, MD doctorRBC ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×